NASDAQ:ABOS Acumen Pharmaceuticals (ABOS) Stock Price, News & Analysis $0.23 -0.01 (-2.21%) Closing price 04:00 PM EasternExtended Trading$0.22 -0.01 (-4.01%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Acumen Pharmaceuticals Stock (NASDAQ:ABOS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Acumen Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.23▼$0.2550-Day Range$0.21▼$3.1852-Week Range$0.20▼$3.60Volume6.08 million shsAverage Volume5.74 million shsMarket Capitalization$16.95 millionP/E RatioN/ADividend YieldN/APrice Target$1.00Consensus RatingReduce Company Overview Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer’s disease and other neurodegenerative disorders. The company’s research centers on amyloid beta oligomers, toxic protein assemblies that Acumen believes contribute to the development and progression of Alzheimer’s disease. Acumen’s lead product candidate is sabirnetug, also known as ACU193, an investigational humanized monoclonal antibody designed to selectively target soluble amyloid beta oligomers. The company is evaluating sabirnetug in clinical studies to assess its safety, tolerability, and potential to slow or modify the progression of early Alzheimer’s disease. Founded in 1996 and headquartered in Charlottesville, Virginia, Acumen has no marketed products and does not currently operate as a commercial pharmaceutical company. Its activities are focused on drug discovery, clinical development, and related research conducted through clinical and scientific collaborations.AI Generated. May Contain Errors. Read More Acumen Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreABOS MarketRank™: 2.656352004175 of 5 starsAcumen Pharmaceuticals scored higher than 53% of companies evaluated by MarketBeat, and ranked 517th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingReduce Consensus RatingAcumen Pharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 3 sell ratings.Upside PotentialAcumen Pharmaceuticals has a consensus price target of $1.00, representing about 326.6% upside from its current price of $0.23.Amount of Analyst CoverageAcumen Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Acumen Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Acumen Pharmaceuticals are expected to decrease in the coming year, from ($1.51) to ($1.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acumen Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acumen Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcumen Pharmaceuticals has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.76% of the float of Acumen Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcumen Pharmaceuticals has a short interest ratio ("days to cover") of 5.43.Change versus previous monthShort interest in Acumen Pharmaceuticals has recently increased by 0.37%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAcumen Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcumen Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment-0.12 News SentimentAcumen Pharmaceuticals has a news sentiment score of -0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Acumen Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest6 people have searched for ABOS on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows3 people have added Acumen Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Acumen Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.20% of the stock of Acumen Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.01% of the stock of Acumen Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Acumen Pharmaceuticals' insider trading history. Receive ABOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABOS Stock News HeadlinesBTIG Sticks to Their Buy Rating for Acumen Pharmaceuticals (ABOS)November 3 at 2:42 AM | theglobeandmail.comAcumen Pharmaceuticals consensus price target decreased by 57.89% to $3.26November 3 at 2:42 AM | msn.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.November 3 at 1:00 AM | Porter & Company (Ad)Acumen Pharmaceuticals (NASDAQ:ABOS) Cut to Strong Sell at Cantor FitzgeraldNovember 2 at 1:24 AM | americanbankingnews.comAcumen Pharmaceuticals (NASDAQ:ABOS) Cut to Hold at CitigroupNovember 2 at 1:24 AM | americanbankingnews.comAcumen Pharmaceuticals (NASDAQ:ABOS) Cut to "Hold" at Stifel NicolausNovember 2 at 1:24 AM | americanbankingnews.comCantor Fitzgerald Downgrades Acumen Pharmaceuticals to Underweight From OverweightOctober 31 at 1:27 PM | marketscreener.comMAcumen plunges on mid-stage trial setback for Alzheimer’s candidateOctober 31 at 1:27 PM | seekingalpha.comSee More Headlines ABOS Stock Analysis - Frequently Asked Questions How have ABOS shares performed this year? Acumen Pharmaceuticals' stock was trading at $2.11 at the beginning of the year. Since then, ABOS shares have decreased by 88.9% and is now trading at $0.2344. How were Acumen Pharmaceuticals' earnings last quarter? Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) issued its earnings results on Monday, October, 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.04. Read the conference call transcript. When did Acumen Pharmaceuticals IPO? Acumen Pharmaceuticals (ABOS) raised $150 million in an IPO on Tuesday, June 29th 2021. The company issued 9,999,999 shares at a price of $14.00-$16.00 per share. How do I buy shares of Acumen Pharmaceuticals? Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Acumen Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acumen Pharmaceuticals investors own include Palantir Technologies (PLTR), Cabaletta Bio (CABA), Caribou Biosciences (CRBU), Archer Aviation (ACHR), Advanced Micro Devices (AMD), Annexon (ANNX) and Ardelyx (ARDX). Company Calendar Last Earnings10/26/2026Today11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 4 days ago, ABOS's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ABOS CIK1576885 Webwww.acumenpharm.com Phone434-297-1000FaxN/AEmployees61Year Founded1996Price Target and Rating Average Price Target for Acumen Pharmaceuticals$1.00 High Price Target$1.00 Low Price Target$1.00 Potential Upside/Downside+326.6%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$121.33 million Net MarginsN/A Pretax MarginN/A Return on Equity-166.49% Return on Assets-90.79% Debt Debt-to-Equity Ratio0.17 Current Ratio1.89 Quick Ratio1.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book0.49Miscellaneous Outstanding Shares72,330,000Free Float64,950,000Market Cap$16.95 million OptionableOptionable Beta0.51 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:ABOS) was last updated on 11/3/2026 by MarketBeat.com Staff. From Our PartnersThe most dangerous moment in a financial crisisDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredU.S. Army Advances 75-Year Rare Earth Deal With Nasdaq FirmThe Pentagon is moving to cut US dependence on Chinese rare earth metals, and a Nasdaq-listed company just sig...The Tomorrow Investor | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredThis little-known fund tracks gold and pays out weeklyA little-known $15 fund tied to gold could pay you cash every Friday, no mining stock required. In one rece...Investors Alley | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABOS Stock Alerts